Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. Iktos offers its technology both as a professional services and as a SaaS software platform. Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software for retrosynthesis.